제목 | [논문] 하상준 교수님_Clinical Perspectives to Overcome Acquired | ||||
---|---|---|---|---|---|
작성자 | 비임파성 장기 면역 연구센터 | 등록일 | 2022-11-22 | 조회수 | 465 |
Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
Immune checkpoint inhibitors have changed the paradigm of treatment options for non-small cell lung cancer (NSCLC). Monoclonal antibodies targeting programmed death-1 (PD- 1) and programmed death ligand-1 (PD-L1) have gained wide attention for their application, which has been shown to result in prolonged survival. Nevertheless, only a limited subset of patients show partial or complete response to PD-1 therapy, and patients who show a response eventually develop resistance to immunotherapy. This article aims to provide an overview of the mechanisms of acquired resistance to anti–PD-1/PD-L1 therapy from the perspective of tumor cells and the surrounding microenvironment. In addition, we address the potential therapeutic targets and ongoing clinical trials, focusing mainly on NSCLC. |
이전글 | [논문] 배외식 교수님_Isovaleric acid ameliorates ovariectomy-induced |
---|---|
다음글 | [논문] 배용수 교수님_Therapeutic Potential of microRNA Against Th2-associated Immune Disorders |